- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis
David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
As the pathophysiology of atopic dermatitis differs across patients, better comprehension is warranted on how specific novel therapies may impact outcomes among these varying populations, said David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology.
Dr Stukus was interviewed prior to the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, which ran from November 4-8, 2021.
Transcript
With several new therapies possibly being approved for atopic dermatitis, is there anything in particular you will be watching for, or hoping to see, that pertains to your patients?
I think the pressing question is how do we identify which patients are going to respond best to which option, because all of these wonderful new biologic therapies and other treatment options have very specific ways that they sort of interact with the immune system. And we know with atopic dermatitis, it's not necessarily one size fits all.
There may be different underlying mechanisms in regards to the immune system as contributors or triggers. So, I think the biggest thing is, as all of these new wonderful treatment options become available, how do we find the best fit for the best patient? And then how do we actually determine whether or not it's working or not? So, I think that we have a lot of unanswered questions, and I think the sessions at the meeting are going to help hopefully start to answer some of those.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
